Surveillance Data for ZAYNICH™
Susceptibility of ZAYNICH™ tested against a large collection of clinical isolates
Study design: 9,087 isolates were evaluated, including 8,472 from the SENTRY Surveillance Program in 2022, and 615 supplemental carbapenem-resistant isolates. In total, there were 704 carbapenem-resistant isolates from multiple countries and international regions.
In this study, ZAYNICH™ was the most potent agent tested against isolates with an ESBL- or carbapenem-resistant phenotype
| Resistance mechanism | Isolates | ZAYNICH™ | Cefiderocol | Ceftazidime/ avibactam |
Meropenem/ vaborbactam |
Imipenem/ relebactam |
|---|---|---|---|---|---|---|
| Overall CRE (carbapenem-resistant Enterobacterales) | 301 | 95.3% | 96% | 34.2% | 27.6% | 19.9% |
| MBL (metallo-β-lactamase)-producing | 197 | 92.8% | 93% | 2% | 14.2% | 1% |
| KPC (Klebsiella pneumoniae carbapenemase)-producing | 53 | 100% | 100% | 90.6% | 92.5% | 92.5% |
| OXA-48-like-producing | 51 | 100% | 100% | 100% | 11.8% | 17.6% |
| Carbapenem-resistant P. aeruginosa (CRPA) | 203 | 96.1% | 95.1% | 43.3% | N/A | 46.3% |
| MBL | 101 | 96% | 90.1% | 3% | N/A | 4% |
| Non-MBL | 102 | 96.1% | 100% | 83.3% | N/A | 88.2% |
In vitro activity does not necessarily correlate with clinical efficacy results.
Reference: 1. Data on File.